US President Donald Trump defended his family's cryptocurrency business, World Liberty Financial, stating he has no involvement in its operations and cannot stop his sons from running it while he is in office. The company faces scrutiny over a $500 million investment linked to a UAE national security adviser, raising conflict of interest concerns. Democrats plan investigations into the Trump family's business dealings, focusing on foreign crypto investments and regulatory compliance. The situation highlights ongoing questions about political influence and transparency in crypto ventures linked to public officials.
Donald Trump's family cryptocurrency business is the subject, providing market context for readers. For those following cryptocurrency, here is Pluang's market snapshot as of Nov 09, 2026 12:41 WIB: Out of 50 major cryptocurrencies, 7 rose and 42 fell. Notable movers include SAND at Rp745 with a 1-day change of -3.51%, KSM at Rp56.224 with -3.40%, and AXS at Rp14.442 with -3.39%.
Bitcoin briefly fell below $74,000 on Nov. 8 as over $1 billion in leveraged crypto positions were forcibly closed ahead of upcoming U.S. inflation data. It later recovered above $75,000. Over five U.S. trading sessions ending Nov. 6, Bitcoin ETFs sa...
XRP has sharply declined against Bitcoin, losing nearly 8% of its value over the past week amid a broader cryptocurrency market downturn. The coin dropped 4.9% in the last 24 hours and is currently priced around $1.10. This decline is more severe tha...
Dapirolizumab pegol (DZP), an investigational biologic for systemic lupus erythematosus (SLE), demonstrated greater treatment response rates compared to placebo when combined with standard care in the Phase 3 PHOENYCS GO trial. Using a novel Treatmen...
argenx will acquire Unnatural Products (UNP) for $550 million upfront plus up to $600 million in milestones, totaling about $1.15 billion. UNP specializes in orally-delivered macrocyclic peptides targeting previously undruggable diseases, enhancing a...
Valneva announced positive Phase 2 trial results for its tetravalent Shigella vaccine candidate S4V2, showing a favorable safety profile and encouraging immune responses in infants and adults. The infant trial in Kenya demonstrated significant antibo...
